REPLY:

Thank you very much for your interest and insight regarding our study. We agree that any potential clinical implementation of contrast-enhanced MR neurography for trauma would require a thoughtful risk-benefit analysis. However, the current widespread use and established safety profile of Gd-DTPA would be conducive to implementation. Regarding our noncontrast data, at your suggestion, we performed ROI-based SNR measurements on our T2-weighted sequences using the same approach described in the original article.

Between days 3 and 7, forceps-injured nerves did indeed demonstrate higher T2 signal compared with clip-injured nerves, both when comparing mean SNR of each group ($P = .02$) and when directly comparing injured nerves with their contralateral, non-operative counterparts ($P = .04$). This difference was best de-

tected using the contralateral, normal nerve as an internal control: Using this methodology, we found that forceps-injured nerves demonstrated 44% more T2 signal, while clip-injured nerves demonstrated 31% more T2 signal.

We agree that the relationship between T2 signal changes and Gd-DTPA enhancement warrants further investigation. Potentially, a multiparametric approach including T2 signal hyperintensity, enhancement data, and diffusion tractography would yield the greatest prognostic value.

B. Hill

Department of Radiology
Miller School of Medicine

K. Padgett

Departments of Radiology and Radiation Oncology, Miller School of Medicine
Department of Biomedical Engineering, College of Engineering

V. Karla

Miller School of Medicine

R. Quencer

Department of Radiology
Miller School of Medicine, University of Miami
Miami, Florida

<http://dx.doi.org/10.3174/ajnr.A5661>